Generated by AI
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company develops and commercializes drug-device therapies designed to deliver high-dose chemotherapy directly to the liver while limiting systemic exposure and related side effects. Its current product portfolio includes HEPZATO KIT in the United States and CHEMOSAT in Europe, both used in hepatic delivery procedures for liver cancer care. Delcath Systems serves specialized oncology centers and medical professionals that treat patients with liver tumors, positioning its technologies within the broader medical device and specialty pharmaceutical markets. Headquartered in Queensbury, New York, Delcath Systems plays a focused role in targeted cancer treatment by combining pharmaceutical and device-based approaches for liver-directed therapy.
Website566 Queensbury Avenue
Queensbury, NY, 12804
United States
The latest articles about DCTH.
Delcath stock is downgraded to a hold, as upside may need colorectal and breast cancer trial success, with colorectal data due mid-2027.
Summary of Nov 11's posts. Generated by AI.
Summary of Nov 9's posts. Generated by AI.
Summary of Aug 8's posts. Generated by AI.
Summary of Aug 6's posts. Generated by AI.
Investors talking about DCTH also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.